Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly contributed to China's technological innovation and industrial upgrading over the past six years, with 588 companies successfully listed and total fundraising exceeding 1 trillion yuan [1][3] - The STAR Market has fostered a high level of R&D investment among listed companies, leading to breakthroughs in "hard technology" and the transformation of core technologies into industrial advantages [2][4] - The recent "STAR Market Eight Articles" reform aims to enhance the capital market's adaptability to technological innovation, marking a new phase of reform and providing a foundation for further capital market development [1][8] Group 1: Market Performance and Impact - As of June 12, 2025, the total market capitalization of STAR Market companies exceeded 6.8 trillion yuan, with over 80% belonging to strategic emerging industries and high-tech sectors [3] - In the past six years, STAR Market companies raised 923.2 billion yuan through IPOs and 183.1 billion yuan through refinancing, totaling over 1 trillion yuan [3][4] Group 2: R&D Investment and Achievements - In 2024, STAR Market companies' total R&D investment reached 168.08 billion yuan, more than 2.5 times their net profit, with a year-on-year growth of 6.4% and a three-year compound growth rate of 10.7% [4] - The median R&D investment as a percentage of operating income was 12.6%, leading A-share markets, with 107 companies maintaining an R&D intensity exceeding 20% for three consecutive years [4] Group 3: International Expansion and Competitiveness - STAR Market companies are increasingly pursuing international markets, with total overseas revenue reaching 430.36 billion yuan in 2024, a year-on-year increase of 6.1% [6] - 173 companies reported over 30% growth in overseas revenue, with 63 companies exporting products to more than 50 countries [6] - Notable examples include the successful entry of domestic products into international markets, such as the FDA approval of a medical device by United Imaging Healthcare [4][5] Group 4: Regulatory Reforms and Future Outlook - The "STAR Market Eight Articles" reform has led to significant activity in mergers and acquisitions, with 106 new transactions announced since its release, totaling over 140 billion yuan [8] - The introduction of new financing regulations has facilitated innovation and R&D investments, with several companies applying for refinancing to support core business projects [9] - The STAR Market is expected to continue its reform trajectory, supporting the growth of more technology enterprises and advancing technological innovation in China's modernization journey [9]

经营质效见韧性 资本市场是促进民营经济发展壮大的重要平台。目前，科创板民营企业占比超八成，市值超3.8万亿 元。 科创板民企首发募集资金超过5300亿元，资金大部分投向研发及产业化项目，加速了各领域的产业升级 与经济发展。 科创板民营企业经营质效、发展活力、投资信心实现稳步提升。2024年度，科创板民营企业合计实现营 收9091.97亿元，实现净利润225.99亿元。其中，195家科创板民营企业的营业收入、净利润双增长，41 家公司营业收入增速超50%，86家公司净利润增速超50%。 结合2024年业绩表现看，158家公司营业收入超10亿元，145家公司净利润超1亿元。部分企业实现跨越 式发展，154家公司上市后营收实现翻番，70家公司净利润实现翻倍或扭亏为盈，形成"创新—资本—产 业"的良性循环。 民营企业的回款效率是实现长期健康发展的重要基础。2024年度，科创板民营企业整体回款情况得到改 善，销售商品、提供劳务收到的现金金额合计1.05万亿元，同比增加3.7%，较收入增速高出2个百分 点。回款效率的提升进一步提高了科创板民营企业研发资金可获得性，为持续创新提供了现金流保障。 研发创新显活力 创新是科创板 ...

Core Insights - In 2024, companies on the Sci-Tech Innovation Board are accelerating the gathering of innovative elements, enhancing innovation momentum, and helping China gain a competitive edge in global technology [1] - Over 80% of Sci-Tech Innovation Board companies focus on import substitution and self-control, with more than 380 companies achieving international advanced levels in over 850 products or technologies [1] Group 1: Innovation and R&D - Since its establishment, the Sci-Tech Innovation Board has maintained a "hard technology" positioning, with high R&D investment and output being a notable characteristic [2] - In the previous year, total R&D investment reached 168.08 billion yuan, exceeding 2.5 times the net profit, with a year-on-year growth of 6.4% and a compound annual growth rate of 10.7% over the last three years [2] - The median R&D investment as a percentage of operating income is 12.6%, leading all A-share sectors, with 107 companies maintaining an R&D intensity exceeding 20% for three consecutive years [2] Group 2: Technology Transfer and Market Impact - Sci-Tech Innovation Board biopharmaceutical companies have pushed 27 domestically developed innovative Class I drugs to market, filling domestic treatment gaps in key areas such as oncology and rare diseases [3] - Medical device companies have achieved over 1,000 Class III medical device product registrations, while semiconductor equipment companies have shipped over 16,000 units in 2024, driving a 39% year-on-year revenue growth [3] Group 3: Domestic Innovation and Global Reach - Companies on the Sci-Tech Innovation Board are accelerating the resolution of technical challenges through independent R&D and industrial mergers, aiming for self-control [4] - For instance, Huahai Qingke has successfully filled domestic gaps in chemical mechanical polishing equipment and has made significant progress in commercializing low-energy high-current ion implantation equipment [4] - Over 60 companies have launched globally innovative products, leading to breakthroughs in fields such as medical equipment and third-generation semiconductors [4] Group 4: Smart and High-End Manufacturing - Companies are deeply involved in artificial intelligence and smart manufacturing, playing a crucial role in upgrading traditional industries [6] - For example, Kede CNC's high-end CNC machine tools have been applied in over 1,300 units in aerospace and aviation sectors, while Iron Construction Heavy Industry has developed over 100 major equipment pieces for significant domestic and international projects [6] - Companies like Hongsoft Technology and Kingsoft Office are embedding AI technology into various sectors, enhancing operational efficiency and driving digital transformation [7]

封面图作者 | 第一财经 任玉明 【今日推荐】 保时捷中国称"不将小米当对手"是误读 近日，有消息称，保时捷CEO奥博穆在2025上海车展期间表示，"保时捷考虑在华停售电动汽车""保 时捷不将小米当对手"。4月29日，保时捷中国回应称，上述消息均是误读。"保时捷在中国仍将坚定 不移地推进电动化进程，也将加快提供产品数智化本土解决方案。我们下一款纯电车型将是全新的纯 电动Cayenne。"（中新经纬） 英伟达要在中国建合资公司？回应称毫无依据 4月29日，有消息援引报道称，在美国限制英伟达H20对华出口之际，英伟达为了维护其在中国市场 的CUDA生态地位，正在低调地启动"B计划"，即考虑在中国设立合资企业，并可能为未来将中国业 务单独拆分做准备。对此，英伟达回应称："这些说法没有任何依据。将毫无根据的主张和猜测作为 事实发表是不负责任的。" 自美国总统特朗普所谓"对等关税"以来，全球零售巨头沃尔玛的态度出现戏剧性变化。从最初要求中 国供应商自行承担高额关税，到短短20天后迫于库存压力选择自行吸收关税、恢复中国进货。据 《南华早报》报道，江苏省和浙江省的部分制造商已接到沃尔玛等美国主要零售商的通知，要求其近 日恢 ...

第一财经每日精选最热门大公司动态，点击「听新闻」，一键收听。 【今日推荐】 保时捷中国称"不将小米当对手"是误读 近日，有消息称，保时捷CEO奥博穆在2025上海车展期间表示，"保时捷考虑在华停售电动汽车""保时 捷不将小米当对手"。4月29日，保时捷中国回应称，上述消息均是误读。"保时捷在中国仍将坚定不移 地推进电动化进程，也将加快提供产品数智化本土解决方案。我们下一款纯电车型将是全新的纯电动 Cayenne。"（中新经纬） 英伟达要在中国建合资公司？回应称毫无依据 4月29日，有消息援引报道称，在美国限制英伟达H20对华出口之际，英伟达为了维护其在中国市场的 CUDA生态地位，正在低调地启动"B计划"，即考虑在中国设立合资企业，并可能为未来将中国业务单 独拆分做准备。对此，英伟达回应称："这些说法没有任何依据。将毫无根据的主张和猜测作为事实发 表是不负责任的。" 沃尔玛通知中国供应商恢复出货 自美国总统特朗普所谓"对等关税"以来，全球零售巨头沃尔玛的态度出现戏剧性变化。从最初要求中国 供应商自行承担高额关税，到短短20天后迫于库存压力选择自行吸收关税、恢复中国进货。据《南华早 报》报道，江苏省和浙江省的部 ...